Genetinės ir ląstelinės terapijos

Genetic and cellular therapy

Advances in gene and cell therapy have opened up new frontiers in medicine, particularly in areas related to promoting muscle growth and treating injuries. Gene editing technologies such as CRISPR-Cas9 have revolutionized our ability to modify genetic material with incredible precision. At the same time, stem cell research offers promising directions for repairing damaged tissue structures and treating degenerative diseases. This article explores the potential of gene editing to promote muscle growth and discusses the application of stem cell research to injury treatment, providing a comprehensive overview based on the latest scientific findings.

Gene editing: potential for boosting muscle growth

Overview of gene editing technologies

  • CRISPR-Cas9
    Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 is a revolutionary gene editing tool that allows for precise, efficient, and cost-effective modification of DNA sequences. Evolved from a bacterial defense system, CRISPR-Cas9 uses a guide RNA that directs the Cas9 enzyme to a specific DNA sequence, where it creates a double-strand break, enabling gene editing.
  • TALENs and ZFNs
    • Transcription Activator-Like Effector Nucleases (TALENs): These are engineered proteins that can be tailored to target specific DNA sequences.
    • Zinc Finger Nucleases (ZFNs): These are synthetic proteins that combine a zinc finger DNA binding domain with a DNA cleavage domain.
      Although TALENs and ZFNs were used before CRISPR-Cas9, they are more complex and less efficient, so CRISPR is considered the preferred technology in current research.

Mechanisms that enable muscle growth through gene editing

  • Myostatin gene inhibition
    Myostatin is a protein that inhibits muscle growth. Mutations in the MSTN gene, which encodes myostatin, lead to increased muscle mass. Gene editing can be used to disrupt the MSTN gene, reducing myostatin levels and promoting muscle hypertrophy.
    • Animal studies: Using CRISPR-Cas9 to disrupt the MSTN gene in mice led to significant muscle growth.
    • Areas of application: Potential treatments for muscle wasting diseases such as muscular dystrophy.
  • IGF-1 gene amplification
    Insulin-like growth factor 1 (IGF-1) plays a critical role in muscle development and regeneration. Increasing IGF-1 expression through gene editing can promote muscle growth and healing.
    • Research results: In animal models, IGF-1 overexpression shows increased muscle mass and strength.
    • Healing potential: May aid in muscle injury recovery and combat age-related muscle loss.

Current research and discoveries

  • Animal studies:
    • Duchenne muscular dystrophy (DMD): CRISPR-Cas9 has been used to correct mutations that cause DMD in mice, restoring dystrophin synthesis and improving muscle function.
    • Improving animal husbandry: Gene editing has helped create cattle and pigs with increased muscle mass by disrupting the MSTN gene.
  • Potential applications for humans:
    • Gene therapy clinical trials: Early-stage clinical trials are investigating the safety and efficacy of gene editing to treat genetic muscle disorders.
    • Improving achievements: There are ethical questions surrounding the use of gene editing to improve athletic performance.

Ethical considerations and regulatory framework

  • Risk of adverse effects: Unexpected genetic changes can have harmful consequences.
  • Germinal level editing: Changes in sperm and eggs can be inherited, raising ethical questions.
  • Regulation: Organizations such as the FDA and EMA regulate gene editing therapies, emphasizing safety and ethical compliance.

Stem cell research: application to trauma healing

Types of stem cells used for muscle regeneration

  • Embryonic stem cells (ESCs):
    • Features: Pluripotent cells, capable of differentiating into any cell type.
    • Application: Potential to generate muscle cells, but ethical issues limit their use.
  • Adult stem cells (satellite cells):
    • Features: Muscle-specific stem cells involved in growth and healing processes.
    • Application: Can be isolated and expanded for autologous transplantation.
  • Induced pluripotent stem cells (iPSCs):

1. Features: Somatic cells reprogrammed to a pluripotent state.

2. Advantages: Avoids ethical issues associated with ESCs and reduces the risk of immune reactions.

Mechanisms of stem cell therapy in the treatment of muscle injuries

  • Differentiation into muscle cells:
    Stem cells can differentiate into myoblasts, which fuse to form new muscle fibers.
    • Process: Stem cells are induced to express muscle-specific genes.
    • Result: Regeneration of damaged muscle tissue, restoring function.
  • Paracrine effects:
    Stem cells secrete growth factors and cytokines that promote tissue healing.
    • Advantages: Promotes angiogenesis, reduces inflammation and stimulates local cells.

Clinical trials and current results

  • Frontal studies:
    • Rodent models: Stem cell transplantation improved muscle regeneration and strength in mice.
    • Large animal studies: Studies in dogs with muscular dystrophy have shown restored muscle function.
  • Human clinical trials:
    • Ongoing clinical trials: Studies to investigate the safety and effectiveness of stem cell therapies in treating conditions such as DMD and ischemia-induced limb diseases.
    • Initial results: Some studies show improved muscle function and slowed disease progression.

Challenges and future directions

  • Risk of immune reaction:
    • Allogeneic transplantation: The possibility that the immune system will react against the donor cells.
    • Solutions: Use of autologous cells or administration of immunosuppressive therapy.
  • Ethical issues:
    • Embryonic stem cells: Ethical issues related to the use of embryonic tissue.
    • Regulatory oversight: Strict guidelines govern stem cell research.
  • Large-scale production of products:
    • Manufacturers' challenges: It is difficult to produce large quantities of stem cells.
    • Quality control: Ensure consistency and safety in cell products.

Genetic and cellular therapies have enormous potential to promote muscle growth and treat injuries. Gene editing technologies such as CRISPR-Cas9 allow for precise modifications that can promote muscle hypertrophy and correct genetic defects. Stem cell research offers promising strategies to help repair damaged muscle tissue through differentiation and paracrine effects. While significant progress has been made, challenges such as ethical issues, immune reactions, and technical limitations remain. Ongoing research and clinical trials continue to pave the way for safe and effective therapies for muscle diseases and injuries.

References

  1. Doudna, JA, & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096.
  2. Joung, JK, & Sander, JD (2013). TALENs: A widely applicable technology for targeted genome editing. Nature Reviews Molecular Cell Biology, 14(1), 49–55.
  3. Urnov, FD, et al. (2010). Genome editing with engineered zinc finger nucleases. Nature Reviews Genetics, 11(9), 636–646.
  4. McPherron, AC, et al. (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature, 387(6628), 83–90.
  5. Qin, L., et al. (2018). CRISPR/Cas9 system-induced mutation of myostatin gene in rabbits. Cellular Physiology and Biochemistry, 47(4), 1668–1679.
  6. Rodgers, BD, & Garikipati, DK (2008). Clinical, agricultural, and evolutionary biology of myostatin: A comparative review. Endocrine Reviews, 29(5), 513–534.
  7. Philippou, A., et al. (2007). The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo, 21(1), 45–54.
  8. Barton-Davis, ER, et al. (1998). Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proceedings of the National Academy of Sciences, 95(26), 15603–15607.
  9. Long, C., et al. (2014). Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA. Science, 345(6201), 1184–1189.
  10. Wang, X., et al. (2015). CRISPR/Cas9-mediated MSTN disruption and heritable mutagenesis in goats causes increased body mass. Scientific Reports, 5, 13878.
  11. ClinicalTrials.gov. (2021). Search of: gene editing AND muscular dystrophy. Retrieved from https://clinicaltrials.gov/
  12. Isasi, R., et al. (2016). Editing policy to fit the genome? Science, 351(6271), 337–339.
  13. Fu, Y., et al. (2013). High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nature Biotechnology, 31(9), 822–826.
  14. National Academies of Sciences, Engineering, and Medicine. (2017). Human genome editing: Science, ethics, and governanceNational Academies Press.
  15. US Food and Drug Administration. (2020). Human gene therapy for genetic disordersRetrieved from https://www.fda.gov/
  16. Thomson, JA, et al. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282(5391), 1145–1147.
  17. Lo, B., & Parham, L. (2009). Ethical issues in stem cell research. Endocrine Reviews, 30(3), 204–213.
  18. Lepper, C., et al. (2011). Adult satellite cells and embryonic muscle progenitors have distinct genetic requirements. Nature, 460(7255), 627–631.
  19. Montarra, D., et al. (2005). Direct isolation of satellite cells for skeletal muscle regeneration. Science, 309(5743), 2064–2067.
  20. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663–676.
  21. Robinton, DA, & Daley, GQ (2012). The promise of induced pluripotent stem cells in research and therapy. Nature, 481(7381), 295–305.
  22. Chargé, SB, & Rudnicki, MA (2004). Cellular and molecular regulation of muscle regeneration. Physiological Reviews, 84(1), 209–238.
  23. Darabi, R., et al. (2012). Human ES- and iPS-derived myogenic progenitors restore DYSTROPHIN and ameliorate pathology in dystrophic mice. Stem Cell, 10(5), 610–619.
  24. Skuk, D., & Tremblay, JP (2011). Intramuscular cell transplantation as a potential treatment of myopathies: Clinical and preclinical studies. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1812(2), 208–217.
  25. Gnecchi, M., et al. (2008). Paracrine mechanisms in adult stem cell signaling and therapy. Circulation Research, 103(11), 1204–1219.
  26. Caplan, AI, & Correa, D. (2011). The MSC: An injury drugstore. Stem Cell, 9(1), 11–15.
  27. Sacco, A., et al. (2010). Self-renewal and expansion of single transplanted muscle stem cells. Nature, 456(7221), 502–506.
  28. Kornegay, JN, et al. (2012). Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mammalian Genome, 23(1-2), 85–108.
  29. US National Library of Medicine. (2021). ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/
  30. Mendell, JR, et al. (2020). Longitudinal effect of gene therapy on muscular dystrophy. New England Journal of Medicine, 383(10), 927–939.
  31. Daley, GQ, & Scadden, DT (2008). Prospects for stem cell-based therapy. Cell, 132(4), 544–548.
  32. Trounson, A., & McDonald, C. (2015). Stem cell therapies in clinical trials: Progress and challenges. Stem Cell, 17(1), 11–22.
  33. Hyun, I. (2010). The bioethics of stem cell research and therapy. The Journal of Clinical Investigation, 120(1), 71–75.
  34. International Society for Stem Cell Research. (2016). Guidelines for stem cell research and clinical translation. Retrieved from https://www.isscr.org/
  35. Zakrzewski, W., et al. (2019). Stem cell therapies for tissue engineering and regenerative medicine. Stem Cells International, 2019, 1–24.
  36. Chen, KG, et al. (2014). Challenges and opportunities for translation of stem cell therapies. Stem Cell, 14(6), 647–656.

← Previous article Next article →

Back to top

Return to the blog